ArticleCureus2024
A Case Report of Atypical Migratory Shulman Syndrome.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic fasciitis (EF), or Shulman syndrome, is a rare connective tissue disorder characterized by symmetrical and painful swelling and with progressive thickening of the skin and soft tissues with the potential involvement of internal organs such as the pleura, pericardium, and kidneys. Patients may also present with fever, myositis, arthritis, neuropathies, and other systemic symptoms. This case report describes a unique multifocal asynchronous soft tissue involvement in Shulman syndrome in a 39-year-old patient, highlighting clinical presentation, histopathological findings, differential diagnoses, treatment modalities, and patient outcomes. Atypical migratory skin lesions must be considered in the diagnosis of EF. Timely recognition of the disease is crucial for optimal treatment and better patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.